First-line avelumab treatment in patients with metastatic Merkel cell carcinoma

• Verfasst von: D'Angelo, Sandra P. [VerfasserIn]
• Verfasst von: Lebbé, C. [VerfasserIn]
• Verfasst von: Mortier, L. [VerfasserIn]
• Verfasst von: Brohl, A. S. [VerfasserIn]
• Verfasst von: Fazio, N. [VerfasserIn]
• Verfasst von: Grob, J. -J. [VerfasserIn]
• Verfasst von: Prinzi, N. [VerfasserIn]
• Verfasst von: Hanna, G. J. [VerfasserIn]
• Verfasst von: Hassel, Jessica C. [VerfasserIn]
• Verfasst von: Kiecker, F. [VerfasserIn]
• Verfasst von: von Heydebreck, A. [VerfasserIn]
• Verfasst von: Güzel, G. [VerfasserIn]
• Verfasst von: Nghiem, P. [VerfasserIn]
• Titel: First-line avelumab treatment in patients with metastatic Merkel cell carcinoma
• Titelzusatz: 4-year follow-up from part B of the JAVELIN Merkel 200 study
• Verf.angabe: S.P. D’Angelo, C. Lebbé, L. Mortier, A.S. Brohl, N. Fazio, J.-J. Grob, N. Prinzi, G.J. Hanna, J.C. Hassel, F. Kiecker, A. von Heydebreck, G. Güzel & P. Nghiem
• E-Jahr: 2024
• Jahr: May 2024
• Umfang: 7 S.
• Illustrationen: Illustrationen
• Fussnoten: Online verfügbar: 13. Mai 2024 ; Gesehen am 02.12.2024
• Titel Quelle: Enthalten in: ESMO open
• Ort Quelle: [London] : Elsevier, 2016
• Jahr Quelle: 2024
• Band/Heft Quelle: 9(2024), 5 vom: Mai, Artikel-ID 103461, Seite 1-7
• ISSN Quelle: 2059-7029
• DOI: doi:10.1016/j.esmoop.2024.103461
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: avelumab
• Sach-SW: immunotherapy
• Sach-SW: Merkel cell carcinoma
• Sach-SW: overall survival
• K10plus-PPN: 1910582670

Abstract

Background - Results from the JAVELIN Merkel 200 study led to the approval of avelumab [an anti-programmed death-ligand 1 (PD-L1) antibody] for the treatment of metastatic Merkel cell carcinoma (mMCC) in multiple countries and its inclusion in the treatment guidelines as a preferred or recommended therapy in this setting. Here, we report 4-year follow-up results from the cohort of patients with mMCC who received avelumab as first-line treatment. - Patients and methods - In part B of JAVELIN Merkel 200, a single-arm, open-label, phase II study, patients with mMCC who had not received prior systemic therapy for metastatic disease received avelumab 10 mg/kg via intravenous infusion every 2 weeks until confirmed disease progression, unacceptable toxicity, or withdrawal. In this analysis, long-term overall survival (OS), patient disposition, and subsequent treatment were analyzed. - Results - In total, 116 patients received first-line avelumab. At the data cutoff (2 February 2022), the median follow-up was 54.3 months (range 48.0-69.7 months). Seven patients (6.0%) remained on treatment and an additional 21 patients remained in follow-up (18.1%); 72 patients (62.1%) had died. The median OS was 20.3 months [95% confidence interval (CI) 12.4-42.0 months], with a 4-year OS rate of 38% (95% CI 29% to 47%). In patients with PD-L1+ or PD-L1− tumors, the 4-year OS rate was 48% (95% CI 26% to 67%) and 35% (95% CI 25% to 45%), respectively. In total, 48 patients (41.4%) received poststudy anticancer drug therapy, most commonly etoposide (20.7%), carboplatin (19.0%), and avelumab (12.1%). - Conclusions - Avelumab first-line monotherapy in patients with mMCC resulted in meaningful long-term OS, which compared favorably with historical studies of first-line chemotherapy. These results further support the role of avelumab as a standard of care for patients with mMCC.